nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—GART—eye—ocular cancer	0.0137	0.124	CbGeAlD
Pemetrexed—SLC46A1—eye—ocular cancer	0.0111	0.101	CbGeAlD
Pemetrexed—GART—lymphoid tissue—ocular cancer	0.00964	0.0875	CbGeAlD
Pemetrexed—ATIC—eye—ocular cancer	0.00929	0.0843	CbGeAlD
Pemetrexed—ATIC—retina—ocular cancer	0.00921	0.0836	CbGeAlD
Pemetrexed—ATIC—epithelium—ocular cancer	0.0085	0.0771	CbGeAlD
Pemetrexed—SLC46A1—lymphoid tissue—ocular cancer	0.00783	0.071	CbGeAlD
Pemetrexed—ATIC—lymphoid tissue—ocular cancer	0.00655	0.0594	CbGeAlD
Pemetrexed—DHFR—eye—ocular cancer	0.00624	0.0566	CbGeAlD
Pemetrexed—DHFR—retina—ocular cancer	0.00619	0.0561	CbGeAlD
Pemetrexed—DCK—retina—ocular cancer	0.00535	0.0486	CbGeAlD
Pemetrexed—TYMS—lymphoid tissue—ocular cancer	0.00444	0.0403	CbGeAlD
Pemetrexed—DHFR—lymphoid tissue—ocular cancer	0.0044	0.0399	CbGeAlD
Pemetrexed—SLC29A1—lymphoid tissue—ocular cancer	0.00398	0.0361	CbGeAlD
Pemetrexed—DCK—lymphoid tissue—ocular cancer	0.0038	0.0345	CbGeAlD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CDK4—ocular cancer	0.002	0.00225	CbGpPWpGaD
Pemetrexed—SLC46A1—Folate Metabolism—TP53—ocular cancer	0.00198	0.00222	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN2B—ocular cancer	0.00188	0.00211	CbGpPWpGaD
Pemetrexed—DHFR—Fluoropyrimidine Activity—TP53—ocular cancer	0.00185	0.00207	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDK2—ocular cancer	0.00184	0.00207	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MDM2—ocular cancer	0.00184	0.00207	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2C—ocular cancer	0.00184	0.00206	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—HDAC1—ocular cancer	0.00183	0.00206	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND2—ocular cancer	0.00183	0.00206	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2C—ocular cancer	0.00179	0.00201	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—E2F1—ocular cancer	0.00179	0.00201	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—CDK2—ocular cancer	0.00176	0.00198	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—RB1—ocular cancer	0.00174	0.00196	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDK4—ocular cancer	0.00174	0.00196	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—RB1—ocular cancer	0.00174	0.00195	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—E2F1—ocular cancer	0.00172	0.00194	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—E2F5—ocular cancer	0.00171	0.00192	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—ocular cancer	0.00168	0.00189	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—E2F4—ocular cancer	0.00167	0.00188	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYBL2—ocular cancer	0.00167	0.00188	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SAG—ocular cancer	0.00165	0.00186	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—E2F2—ocular cancer	0.00164	0.00184	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RBL1—ocular cancer	0.00164	0.00184	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN2B—ocular cancer	0.00164	0.00184	CbGpPWpGaD
Pemetrexed—TYMS—Fluoropyrimidine Activity—TP53—ocular cancer	0.00161	0.00181	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CCND1—ocular cancer	0.00161	0.0018	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2C—ocular cancer	0.0016	0.0018	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—GNA11—ocular cancer	0.00159	0.00178	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—CDKN1B—ocular cancer	0.00156	0.00175	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—ocular cancer	0.00155	0.00175	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—CDK2—ocular cancer	0.00154	0.00173	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—E2F5—ocular cancer	0.00153	0.00172	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—RB1—ocular cancer	0.00152	0.0017	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RBL2—ocular cancer	0.00151	0.00169	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—E2F1—ocular cancer	0.0015	0.00169	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—E2F4—ocular cancer	0.0015	0.00168	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYBL2—ocular cancer	0.0015	0.00168	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—E2F5—ocular cancer	0.00149	0.00168	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDK2—ocular cancer	0.00149	0.00167	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MDM2—ocular cancer	0.00148	0.00166	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—GNAQ—ocular cancer	0.00148	0.00166	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—E2F2—ocular cancer	0.00147	0.00165	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RBL1—ocular cancer	0.00147	0.00165	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—E2F5—ocular cancer	0.00146	0.00164	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—E2F4—ocular cancer	0.00146	0.00164	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYBL2—ocular cancer	0.00146	0.00164	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—RB1—ocular cancer	0.00145	0.00163	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—CDKN1A—ocular cancer	0.00144	0.00161	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RBL1—ocular cancer	0.00143	0.00161	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—E2F2—ocular cancer	0.00143	0.00161	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—E2F4—ocular cancer	0.00143	0.00161	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RBBP4—ocular cancer	0.00142	0.0016	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—E2F3—ocular cancer	0.00142	0.0016	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDK4—ocular cancer	0.00141	0.00158	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RBL1—ocular cancer	0.0014	0.00158	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RPL39—ocular cancer	0.0014	0.00158	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PSPH—ocular cancer	0.00139	0.00157	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—EP300—ocular cancer	0.00137	0.00154	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—CDKN1B—ocular cancer	0.00136	0.00153	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDC25A—ocular cancer	0.00135	0.00152	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—ocular cancer	0.00135	0.00152	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RBL2—ocular cancer	0.00135	0.00151	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—E2F5—ocular cancer	0.00133	0.0015	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—HDAC1—ocular cancer	0.00133	0.00149	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TFDP1—ocular cancer	0.00132	0.00149	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RBL2—ocular cancer	0.00132	0.00148	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—E2F4—ocular cancer	0.00131	0.00147	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYBL2—ocular cancer	0.00131	0.00147	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDK2—ocular cancer	0.0013	0.00146	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MDM2—ocular cancer	0.00129	0.00145	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CCND1—ocular cancer	0.00129	0.00145	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MYC—ocular cancer	0.00129	0.00145	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—E2F2—ocular cancer	0.00128	0.00144	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RBL1—ocular cancer	0.00128	0.00144	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—E2F3—ocular cancer	0.00127	0.00143	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RBBP4—ocular cancer	0.00127	0.00143	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—RB1—ocular cancer	0.00127	0.00142	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—CDKN1A—ocular cancer	0.00125	0.00141	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CDKN1A—ocular cancer	0.00125	0.0014	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—E2F3—ocular cancer	0.00124	0.0014	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RBBP4—ocular cancer	0.00124	0.0014	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.00124	0.0014	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDK4—ocular cancer	0.00123	0.00138	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—RB1—ocular cancer	0.00122	0.00137	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GNA11—ocular cancer	0.00122	0.00137	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDC25A—ocular cancer	0.00121	0.00136	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND3—ocular cancer	0.0012	0.00135	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—EP300—ocular cancer	0.00119	0.00134	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—MYC—ocular cancer	0.00119	0.00134	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TFDP1—ocular cancer	0.00118	0.00133	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDC25A—ocular cancer	0.00118	0.00133	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDKN1B—ocular cancer	0.00118	0.00133	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RBL2—ocular cancer	0.00118	0.00132	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—TFDP1—ocular cancer	0.00115	0.0013	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00114	0.00128	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TFDP1—ocular cancer	0.00113	0.00127	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GNAQ—ocular cancer	0.00113	0.00127	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—CDKN1B—ocular cancer	0.00113	0.00127	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—ocular cancer	0.00113	0.00127	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PSPH—ocular cancer	0.00112	0.00126	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RBBP4—ocular cancer	0.00111	0.00125	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—E2F3—ocular cancer	0.00111	0.00125	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—ocular cancer	0.00109	0.00122	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND3—ocular cancer	0.00107	0.00121	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—RB1—ocular cancer	0.00107	0.0012	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—TP53—ocular cancer	0.00106	0.00119	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—ocular cancer	0.00106	0.00119	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDC25A—ocular cancer	0.00106	0.00119	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND3—ocular cancer	0.00105	0.00118	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—CDKN1A—ocular cancer	0.00104	0.00117	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—MYC—ocular cancer	0.00104	0.00117	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MYC—ocular cancer	0.00103	0.00116	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TFDP1—ocular cancer	0.00103	0.00116	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—CDKN1B—ocular cancer	0.000985	0.00111	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.000983	0.0011	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PSPH—ocular cancer	0.000977	0.0011	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN1B—ocular cancer	0.000952	0.00107	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND3—ocular cancer	0.000936	0.00105	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.000929	0.00104	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—CDKN1A—ocular cancer	0.000909	0.00102	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—ocular cancer	0.000908	0.00102	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—ocular cancer	0.000903	0.00101	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAML2—ocular cancer	0.000899	0.00101	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDK6—ocular cancer	0.000894	0.001	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—CDK4—ocular cancer	0.000892	0.001	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SAG—ocular cancer	0.000886	0.000995	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN1A—ocular cancer	0.000878	0.000987	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—MYC—ocular cancer	0.000864	0.000971	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—ocular cancer	0.00085	0.000955	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GNA11—ocular cancer	0.000843	0.000948	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1B—ocular cancer	0.00083	0.000933	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDK6—ocular cancer	0.000799	0.000898	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—ocular cancer	0.000792	0.00089	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GNAQ—ocular cancer	0.000784	0.000881	CbGpPWpGaD
Pemetrexed—DHFR—Disease—E2F5—ocular cancer	0.000784	0.000881	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDK6—ocular cancer	0.00078	0.000877	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—HDAC1—ocular cancer	0.000769	0.000864	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND2—ocular cancer	0.000769	0.000864	CbGpPWpGaD
Pemetrexed—DHFR—Disease—E2F4—ocular cancer	0.000768	0.000863	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1A—ocular cancer	0.000766	0.000861	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—MYC—ocular cancer	0.000754	0.000847	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RBL1—ocular cancer	0.000753	0.000846	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RPL39—ocular cancer	0.000753	0.000846	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—ocular cancer	0.000741	0.000833	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—ocular cancer	0.000728	0.000818	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK6—ocular cancer	0.000697	0.000784	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2B—ocular cancer	0.000689	0.000774	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.000689	0.000774	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND2—ocular cancer	0.000687	0.000772	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—HDAC1—ocular cancer	0.000687	0.000772	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND2—ocular cancer	0.000671	0.000754	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—HDAC1—ocular cancer	0.000671	0.000754	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HDAC1—ocular cancer	0.000658	0.000739	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GNA11—ocular cancer	0.000657	0.000739	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—ocular cancer	0.000635	0.000714	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—E2F1—ocular cancer	0.000632	0.000711	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.000629	0.000707	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2B—ocular cancer	0.000616	0.000692	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GNAQ—ocular cancer	0.000611	0.000687	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TFDP1—ocular cancer	0.000607	0.000682	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2B—ocular cancer	0.000601	0.000676	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.0006	0.000674	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—HDAC1—ocular cancer	0.0006	0.000674	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND2—ocular cancer	0.0006	0.000674	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN2B—ocular cancer	0.000589	0.000662	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.00058	0.000652	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—E2F1—ocular cancer	0.000565	0.000636	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.000552	0.000621	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—E2F1—ocular cancer	0.000552	0.00062	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDK2—ocular cancer	0.000545	0.000613	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2B—ocular cancer	0.000538	0.000604	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—EP300—ocular cancer	0.00053	0.000596	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDK4—ocular cancer	0.000516	0.000579	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—E2F1—ocular cancer	0.000493	0.000555	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDK2—ocular cancer	0.000488	0.000548	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAML2—ocular cancer	0.000482	0.000542	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.000481	0.000541	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.00048	0.00054	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDK2—ocular cancer	0.000476	0.000535	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDK4—ocular cancer	0.000461	0.000518	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDK4—ocular cancer	0.00045	0.000506	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RB1—ocular cancer	0.000448	0.000504	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GNA11—ocular cancer	0.000438	0.000493	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK2—ocular cancer	0.000426	0.000478	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GNAQ—ocular cancer	0.000408	0.000458	CbGpPWpGaD
Pemetrexed—GART—Metabolism—EP300—ocular cancer	0.000407	0.000457	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK4—ocular cancer	0.000402	0.000452	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RB1—ocular cancer	0.000401	0.00045	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.000395	0.000444	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RB1—ocular cancer	0.000391	0.00044	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—ocular cancer	0.000379	0.000426	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HDAC1—ocular cancer	0.000353	0.000396	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GNA11—ocular cancer	0.000352	0.000396	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RB1—ocular cancer	0.00035	0.000393	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1B—ocular cancer	0.000349	0.000392	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MDM2—ocular cancer	0.000342	0.000384	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.000334	0.000375	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—ocular cancer	0.000333	0.000374	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GNAQ—ocular cancer	0.000328	0.000368	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MDM2—ocular cancer	0.000327	0.000367	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—ocular cancer	0.000322	0.000362	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN2B—ocular cancer	0.000316	0.000355	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1B—ocular cancer	0.000312	0.000351	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GNA11—ocular cancer	0.000307	0.000346	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EP300—ocular cancer	0.000306	0.000344	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1B—ocular cancer	0.000305	0.000342	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1B—ocular cancer	0.000299	0.000336	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MDM2—ocular cancer	0.000298	0.000335	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—ocular cancer	0.000298	0.000335	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—ocular cancer	0.00029	0.000326	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—ocular cancer	0.000288	0.000324	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GNAQ—ocular cancer	0.000286	0.000321	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—EP300—ocular cancer	0.000282	0.000317	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—ocular cancer	0.000281	0.000316	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—ocular cancer	0.000276	0.00031	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EP300—ocular cancer	0.000274	0.000308	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1B—ocular cancer	0.000272	0.000306	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EP300—ocular cancer	0.000267	0.000301	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—ocular cancer	0.000267	0.0003	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EP300—ocular cancer	0.000262	0.000295	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—ocular cancer	0.00026	0.000292	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—ocular cancer	0.000251	0.000282	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—ocular cancer	0.000246	0.000276	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EP300—ocular cancer	0.000239	0.000269	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—ocular cancer	0.000239	0.000268	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—ocular cancer	0.000233	0.000262	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—ocular cancer	0.000228	0.000257	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFB1—ocular cancer	0.000228	0.000256	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—EP300—ocular cancer	0.00022	0.000247	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—ocular cancer	0.000208	0.000234	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—ocular cancer	0.000196	0.00022	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—ocular cancer	0.000179	0.000202	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MDM2—ocular cancer	0.000175	0.000197	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—ocular cancer	0.000171	0.000192	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—ocular cancer	0.00017	0.000191	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1B—ocular cancer	0.00016	0.00018	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—ocular cancer	0.000158	0.000178	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—ocular cancer	0.000148	0.000166	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—EP300—ocular cancer	0.000146	0.000165	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EP300—ocular cancer	0.000141	0.000158	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—ocular cancer	0.000133	0.000149	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—ocular cancer	0.000122	0.000138	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFB1—ocular cancer	0.000122	0.000137	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—EP300—ocular cancer	0.000118	0.000132	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—EP300—ocular cancer	0.000103	0.000115	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—ocular cancer	9.62e-05	0.000108	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—ocular cancer	8.85e-05	9.95e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—ocular cancer	8.49e-05	9.55e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—ocular cancer	7.11e-05	7.99e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—ocular cancer	6.21e-05	6.98e-05	CbGpPWpGaD
